Eurobio Scientific Société anonyme Toekomstige groei

Future criteriumcontroles 3/6

Eurobio Scientific Société anonyme zal naar verwachting groeien in winst en omzet met respectievelijk 29% en 3.9% per jaar. De winst per aandeel zal naar verwachting groeien met 30.9% per jaar. Het rendement op het eigen vermogen zal over 3 jaar naar verwachting 10.5% zijn.

Belangrijke informatie

29.0%

Groei van de winst

30.9%

Groei van de winst per aandeel

Biotechs winstgroei	4.6%
Inkomstengroei	3.9%
Toekomstig rendement op eigen vermogen	10.5%
Dekking van analisten	Low
Laatst bijgewerkt	25 Oct 2024

Recente toekomstige groei-updates

Recent updates

Eurobio Scientific Société anonyme (EPA:ALERS) Held Back By Insufficient Growth Even After Shares Climb 32%

Jul 31

Calculating The Intrinsic Value Of Eurobio Scientific Société anonyme (EPA:ALERS)

Jul 29

Estimating The Fair Value Of Eurobio Scientific Société anonyme (EPA:ALERS)

Apr 07

Is Now The Time To Put Eurobio Scientific Société anonyme (EPA:ALERS) On Your Watchlist?

Mar 08

Calculating The Intrinsic Value Of Eurobio Scientific Société anonyme (EPA:ALERS)

Jan 03

Improved Earnings Required Before Eurobio Scientific Société anonyme (EPA:ALERS) Stock's 28% Jump Looks Justified

Dec 13

Should You Be Adding Eurobio Scientific Société anonyme (EPA:ALERS) To Your Watchlist Today?

Nov 20

Eurobio Scientific Société anonyme's (EPA:ALERS) Earnings Are Of Questionable Quality

May 12

Winst- en omzetgroeiprognoses

ENXTPA:ALERS - Toekomstschattingen van analisten en financiële gegevens uit het verleden (EUR Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
12/31/2026	156	15	25	27	1
12/31/2025	148	11	21	24	1
12/31/2024	138	9	17	20	1
6/30/2024	145	7	20	23	N/A
3/31/2024	138	6	21	25	N/A
12/31/2023	131	5	23	27	N/A
9/30/2023	129	6	23	28	N/A
6/30/2023	128	8	24	29	N/A
3/31/2023	140	16	32	36	N/A
12/31/2022	153	25	40	43	N/A
9/30/2022	163	36	N/A	N/A	N/A
6/30/2022	174	47	60	61	N/A
3/31/2022	180	54	62	64	N/A
12/31/2021	185	61	64	66	N/A
9/30/2021	204	71	N/A	N/A	N/A
6/30/2021	223	81	83	85	N/A
3/31/2021	206	77	68	70	N/A
12/31/2020	189	73	53	55	N/A
9/30/2020	141	51	29	30	N/A
6/30/2020	92	28	5	5	N/A
3/31/2020	76	16	4	5	N/A
12/31/2019	59	3	3	5	N/A
9/30/2019	58	1	2	3	N/A
6/30/2019	56	-2	0	2	N/A
3/31/2019	53	-2	-1	1	N/A
12/31/2018	51	-3	-2	-1	N/A
9/30/2018	50	-4	-3	0	N/A
6/30/2018	48	-6	-4	1	N/A
3/31/2018	46	-8	N/A	2	N/A
12/31/2017	43	-10	N/A	2	N/A
9/30/2017	38	-9	N/A	0	N/A
6/30/2017	32	-9	N/A	-2	N/A
3/31/2017	30	-8	N/A	-2	N/A
12/31/2016	28	-8	N/A	-3	N/A
9/30/2016	28	-8	N/A	N/A	N/A
6/30/2016	29	-8	N/A	-4	N/A
3/31/2016	29	-7	N/A	-3	N/A
12/31/2015	30	-6	N/A	-2	N/A
9/30/2015	30	-6	N/A	N/A	N/A
6/30/2015	31	-6	N/A	-3	N/A
3/31/2015	31	-6	N/A	-3	N/A
12/31/2014	31	-5	N/A	-3	N/A
9/30/2014	31	-5	N/A	-3	N/A
6/30/2014	31	-5	N/A	-4	N/A
3/31/2014	31	-6	N/A	-4	N/A
12/31/2013	31	-6	N/A	-5	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: De verwachte winstgroei ALERS ( 29% per jaar) ligt boven de spaarquote ( 1.4% ).

Winst versus markt: De winst van ALERS ( 29% per jaar) zal naar verwachting sneller groeien dan de French markt ( 12.6% per jaar).

Hoge groeiwinsten: De winst van ALERS zal naar verwachting de komende 3 jaar aanzienlijk groeien.

Omzet versus markt: De omzet van ALERS ( 3.9% per jaar) zal naar verwachting langzamer groeien dan de markt French ( 5.6% per jaar).

Hoge groei-inkomsten: De omzet van ALERS ( 3.9% per jaar) zal naar verwachting langzamer groeien dan 20% per jaar.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Het rendement op eigen vermogen ALERS zal naar verwachting over 3 jaar laag zijn ( 10.5 %).

Eurobio Scientific Société anonyme Toekomstige groei

Future criteriumcontroles 3/6

Belangrijke informatie

Recente toekomstige groei-updates

Price target increased by 7.1% to €30.00

Price target increased by 7.4% to €29.00

Consensus EPS estimates increase by 30%

Price target increased by 7.7% to €28.00

Price target decreased to €32.00

Price target decreased to €35.00

Recent updates

Diaxonhit ORD to Be Deleted from OTC Equity

First half 2024 earnings released: EPS: €0.40 (vs €0.21 in 1H 2023)

Investor sentiment improves as stock rises 45%

NextStage AM, IK Partners, Denis Fortier, Cathie Marsais, Olivier Bosc, JeanMichel Carle-Grandmougin and Hervé Duchesne de Lamotte proposed to acquire remaining 65.96% stake in Eurobio Scientific Société anonyme (ENXTPA:ALERS) from Wietse Mulder and others for approximately €170 million.

Eurobio Scientific Société anonyme (EPA:ALERS) Held Back By Insufficient Growth Even After Shares Climb 32%

Investor sentiment improves as stock rises 16%

Full year 2023 earnings released

Price target increased by 7.1% to €30.00

Eurobio Scientific Société anonyme, Annual General Meeting, Jun 13, 2024

Eurobio Scientific Société anonyme to Report Fiscal Year 2023 Results on Apr 10, 2024

Price target increased by 7.4% to €29.00

Eurobio Scientific Société anonyme (ENXTPA:ALERS) acquired Alpha Biotech Ltd.

Eurobio Scientific Appoints Catherine Courboillet to the Board of Directors

Investor sentiment improves as stock rises 16%

Consensus EPS estimates increase by 30%

First half 2023 earnings released

Now 20% undervalued after recent price drop

Price target increased by 7.7% to €28.00

Full year 2022 earnings released

Eurobio Scientific Société anonyme to Report First Half, 2023 Results on Oct 11, 2023

Less than half of directors are independent

First half 2022 earnings released

Eurobio Scientific Société anonyme, Annual General Meeting, Jun 12, 2023

Investor sentiment improved over the past week

Price target decreased to €32.00

Eurobio Scientific Société anonyme (ENXTPA:ALERS) acquired Genome Diagnostics B.V. from from Ampersand Capital Partners and others.

Now 21% undervalued after recent price drop

Now 22% undervalued after recent price drop

Eurobio Scientific Société anonyme (ENXTPA:ALERS) agreed to acquire Genome Diagnostics B.V. for ?135 million.

Eurobio Scientific Société anonyme (ENXTPA:ALERS) agreed to acquire Genome Diagnostics B.V. for ?135 million.

Calculating The Intrinsic Value Of Eurobio Scientific Société anonyme (EPA:ALERS)

Price target decreased to €35.00

Eurobio Scientific Société anonyme to Report First Half, 2022 Results on Oct 11, 2022

Eurobio Scientific Launches 2 New Proprietary Tests for the Diagnosis of New Variants of Sars-Cov-2 and Monkeypox

Eurobio Scientific Société anonyme (ENXTPA : ALERS) acquired Biomedical Diagnostics Belgium.

No independent directors

Investor sentiment deteriorated over the past week

Full year 2021 earnings released

Eurobio Scientific Société anonyme, Annual General Meeting, Jun 13, 2022

Estimating The Fair Value Of Eurobio Scientific Société anonyme (EPA:ALERS)

Is Now The Time To Put Eurobio Scientific Société anonyme (EPA:ALERS) On Your Watchlist?

Calculating The Intrinsic Value Of Eurobio Scientific Société anonyme (EPA:ALERS)

Investor sentiment improved over the past week

Improved Earnings Required Before Eurobio Scientific Société anonyme (EPA:ALERS) Stock's 28% Jump Looks Justified

Eurobio Scientific Launches the First Pcr Test Allowing Simultaneous Sars-Cov-2 Virus Screening and Detection of the Delta and Omicron Variants in a Single Reaction

Should You Be Adding Eurobio Scientific Société anonyme (EPA:ALERS) To Your Watchlist Today?

First half 2021 earnings released

Investor sentiment improved over the past week

Eurobio Scientific launches its COVID antigen self-test

Eurobio Scientific Offers A New Proprietary Test for Simultaneous Detection of the SARS-COV-2 Virus and Characterization of Its New Mutations of Interest

Eurobio Scientific Société anonyme's (EPA:ALERS) Earnings Are Of Questionable Quality

Full year 2020 earnings released

Eurobio Scientific Announces Launch of New Proprietary Test, EurobioPlex SARS-CoV-2 Variants

Eurobio Scientific Société anonyme to Report Fiscal Year 2020 Results on Apr 14, 2021

Eurobio Scientific Expands Its Range of COVID-19 Tests with an Antigenic Rapid Test

Investor sentiment improved over the past week

Investor sentiment improved over the past week

New 90-day high: €18.35

Market bids up stock over the past week

Market bids up stock over the past week

Market pulls back on stock over the past week

New 90-day high: €17.10

New 90-day high: €13.90

Eurobio Scientific SociÃ©tÃ© anonyme to Report First Half, 2020 Results on Oct 15, 2020

Eurobio Scientific Launches A First Rapid Diagnostic Test for the Detection of the SARS CoV-2 virus antigen

New 90-day high: €13.05

New 90-day high - €12.35

Eurobio Scientific Société anonyme (ENXTPA:ALERS) acquired TECOmedical AG.

Winst- en omzetgroeiprognoses